Targets › CLN5
1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Nov 2028.
[Bis(monoacylglycero)phosphate synthase CLN5, secreted form]: Catalyzes the synthesis of bis(monoacylglycero)phosphate (BMP) via transacylation of 2 molecules of lysophosphatidylglycerol (LPG). BMP also known as lysobisphosphatidic acid plays a key role in the formation of intraluminal vesicles and in maintaining intracellular cholesterol homeostasis. (UniProt, O75503)
Open in Phaseline: the race on CLN5, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Neurogene | NGN-101 Gene therapy for CLN5 deficiency delivered via intracerebroventricular and intravitreal in | CLN5 | Phase 1 | Neuronal Ceroid Lipofuscinosis CLN5 | Nov 2028 |
Neuronal Ceroid Lipofuscinosis CLN5 (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.